HER2 + BREAST CANCER

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This study compares a combination of two drugs (elacestrant and capecitabine) to capecitabine alone in people with advanced estrogen receptor-positive breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to one of the two t…

This early-stage trial tests a new drug called IAM1363 in adults with advanced cancers that have HER2 alterations, including breast, lung, and stomach cancers that have spread to the brain. The study aims to find the safest dose and see if the drug can shrink tumors. About 383 pa…

This study tests whether giving a precise, high-dose radiation treatment called SBRT to one growing tumor can help people with metastatic breast cancer keep their disease under control. Participants continue their usual drug therapy while receiving SBRT to a single site where can…

This study tests whether combining two experimental drugs (HLX22 and HLX87) works better as a first treatment for HER2-positive breast cancer that has returned or spread. About 706 adults with advanced or metastatic breast cancer will participate. The main goals are to see how ma…

This phase 2 trial is testing whether giving a short course of radiation (SBRT) and two injections of the immunotherapy drug pembrolizumab (Keytruda) before standard chemotherapy can improve outcomes for people with stage 2 or 3 breast cancer. The study aims to see if this combin…

This study tests whether a combination of two targeted drugs (trastuzumab deruxtecan and pertuzumab) can shrink or eliminate HER2-positive breast tumors before surgery. About 50 women with stage II-III breast cancer will receive the drugs for three cycles. If the tumor responds w…

This early-stage trial is testing a new drug called [177Lu]Lu-ABY-271, which delivers a small dose of radiation directly to HER2-positive breast cancer cells. The study will enroll 21 people with advanced or metastatic HER2-positive breast cancer to see if the drug is safe, toler…

This study is looking at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. These leftover cells, called minimal residual disease (MRD), can sometimes cause the cancer to come back. The study will follow 900 breast cancer …

This study is for 500 adults with non-metastatic breast cancer who are about to start treatment like chemotherapy or targeted therapy before surgery. Researchers will collect tumor tissue, blood, and sometimes stool samples and MRI scans during treatment. The goal is to learn why…

This observational study will follow 1000 people with HER2-positive breast cancer to see how patient and tumor characteristics relate to outcomes like survival and treatment response. Participants are not given any new treatment—researchers simply collect data over time. The goal…